Search

Your search keyword '"Nishihara, Fuyumi"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Nishihara, Fuyumi" Remove constraint Author: "Nishihara, Fuyumi"
46 results on '"Nishihara, Fuyumi"'

Search Results

4. Supplementary Figure Legends from CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

5. Data from CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

6. Supplementary Figures and Tables from CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

7. Data from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

8. Table S1, S3 and S8 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

9. Figure S1,S2,S3,S4,S5,S6,S7,S8,S9 and S10 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

10. Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

11. Supplementary materials from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

12. Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy

14. Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1.

16. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

17. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

18. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

19. Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

20. CD4+ T-cell immunity predicts long-lasting antitumor immunity after PD-1 blockade therapy.

21. Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

22. Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

23. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

25. Correlation of PBMC CD62Llow CD4+ T cells with irILD after nivolumab therapy.

28. CD4+ T cells in PBMC to predict the outcome of anti-PD-1 therapy.

31. Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.

38. The Clinical Study Of Hypoxia During Sleep In Patients With Severe Sleep Apnea

40. Mycobacterium gordonae-induced humidifier lung.

41. CD4 + T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.

42. Trans-basement membrane migration of eosinophils induced by LPS-stimulated neutrophils from human peripheral blood in vitro .

43. [Rapid specific IgE assay (ImmunoCAP® RAPID) and skin prick test in the diagnosis of allergic disease].

44. [Effects of educational guidance on airway inflammation of patients with severe persistent asthma].

45. [A case of bronchial asthma caused by occupational exposure to trichophyton].

46. [Questionnaire for determining relationship between nasal and asthma symptoms].

Catalog

Books, media, physical & digital resources